GC Green Cross Wellbeing Confirms Pain Relief Effect of Placenta Injection Drug 'Linek'

[Asia Economy Reporter Cho Hyun-ui] GC Green Cross Wellbeing's placenta injection drug 'Rainek' has been found to have pain relief effects. Rainek is a liver function improvement agent for patients with alcoholic and non-alcoholic steatohepatitis.

On the 16th, GC Green Cross Wellbeing announced that a paper confirming the therapeutic effect of hydrolyzed human placenta Rainek on fibromyalgia was published in the international journal 'Physiotherapy Research and Reports.'

Fibromyalgia is a disease characterized by chronic widespread pain, sleep disturbances, cognitive impairment, and increased fatigue without a specific cause. It is found in about 4% of the population and is especially common in women over their 40s.

This paper is the result of a joint study conducted by GC Green Cross Wellbeing and Directors Cho Tae-hwan and Park Kyung-mi (Cho Tae-hwan Orthopedic Clinic) involving a total of 64 fibromyalgia patients.

After administering Rainek once a week for 5 weeks to the patients' pain trigger points, the pain assessment scale score (0?10 points) decreased from 3?7 to an average of about 1. The sleep disturbance scale score (0?3 points) also improved from an average of 2 to about 0, and the 'vitality time,' which indicates the time spent living without pain during the day, increased from an average of 6 hours to 9 hours.

Director Cho Tae-hwan, who participated in the study, said, “We confirmed that Rainek can help relieve pain and improve the quality of life for fibromyalgia patients,” adding, “Since fibromyalgia involves not only chronic pain but also various symptoms, this result is even more meaningful.”

Meanwhile, GC Green Cross Wellbeing is currently conducting antiviral research on the novel coronavirus infection (COVID-19), including recently filing domestic patents for Rainek and placenta-derived substances.

This content was produced with the assistance of AI translation services.